TABLE 17.

Third-line regimen recommended for the majority of patients failing protease inhibitor-based second-line therapy.

Failing second-line regimen	Advised third-line regimen
Protease inhibitor-based therapy	TDF 300 mg daily, 3TC 300 mg daily, DTG 50 mg daily (given as TLD) plus DRV/r 600 mg/100 mg twice daily

3TC, lamivudine; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; TDF, tenofovir disoproxil fumarate; TLD, tenofovir disoproxil fumarate + lamivudine + dolutegravir fixed-dose combination.